mometasone-furoate and Facial-Dermatoses

Facial seborrheic dermatitis (SD), a chronic inflammatory skin condition, can impact quality of life, and relapses can be frequent. Three broad categories of agents are used to treat SD: antifungal agents, keratolytics, and corticosteroids. Topical therapies are the first line of defense in treating this condition.. Our objective was to critically review the published literature on topical treatments for facial SD.. We searched PubMed, Scopus, Clinicaltrials.gov, MEDLINE, Embase, and Cochrane library databases for original clinical studies evaluating topical treatments for SD. We then conducted both a critical analysis of the selected studies by grading the evidence and a qualitative comparison of results among and within studies.. A total of 32 studies were eligible for inclusion, encompassing 18 topical treatments for facial SD. Pimecrolimus, the focus of seven of the 32 eligible studies, was the most commonly studied topical treatment.. Promiseb

Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Antifungal Agents; Calcineurin Inhibitors; Ciclopirox; Dermatitis, Seborrheic; Dermatologic Agents; Desonide; Facial Dermatoses; Humans; Ketoconazole; Malassezia; Mometasone Furoate; Plant Preparations; Practice Guidelines as Topic; Pyridones; Quality of Life; Randomized Controlled Trials as Topic; Tacrolimus; Treatment Outcome; Vitamins

Topics: Anti-Inflammatory Agents; Arm; Facial Dermatoses; Female; Granuloma; Humans; Middle Aged; Mometasone Furoate; Neck; Pregnadienediols; Treatment Outcome

Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Dermatitis, Atopic; Facial Dermatoses; Follow-Up Studies; Glucocorticoids; Humans; Intertrigo; Mometasone Furoate; Ointments; Pregnadienediols; Psoriasis; Safety; Time Factors